Vyteris regains right to market Actyve in physicians' offices

By Ted A. Knutson

Washington, March 13 - Vyteris Holdings (Nevada), Inc. said it amended an agreement on March 7 with B. Braun Medical, Inc. so that Vyteris has recovered the ability to market, sell and distribute its Actyve transdermal drug delivery product in the physician's office and Japanese markets.

In the amended pact, Braun has agreed to refrain from marketing, selling and distributing its branded version of that product in these markets.

In addition, the amendment resets the first contract year under the license, development and distribution agreement between the two companies to 2006, with no minimum purchase requirement during that year.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

Vyteris Holdings (Nevada) is a specialty pharmaceutical company based in Fair Lawn, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.